Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody and
cyclophosphamide in treating patients with metastatic cancer.